Novartis’ Sandoz to acquire Aspen Japan for $331m
Novartis subsidiary Sandoz has signed an agreement to buy Aspen Japan operations and related intellectual...
Read More...
Focus:
-
![pharma patents manipulation]()
From evergreening to thicketing: exploring the manipulation of pharma patents
The drug patent system was created to reward pharma companies for innovation and ensure returns...
Read More...
-
![Takeda Ninlaro multiple myeloma]()
Takeda’s Ninlaro meets primary endpoint in multiple myeloma
Takeda has announced that Ninlaro (ixazomib) has met its primary endpoint of progression-free survival (PFS)...
Read More...
-
![]()
Risk management in the pharmaceutical supply chain
As production and distribution through the pharmaceutical supply chain grows increasingly globalised and complex, stringent...
Read More...
-
![Descovy Truvada HIV PrEP]()
Gilead demonstrates non-inferiority of Descovy to Truvada for HIV PrEP
Gilead Sciences has published data from the Phase III 96-week DISCOVER trial in which Descovy...
Read More...
-
![Regeneron and Vyriad to develop oncolytic virus therapies]()
Regeneron and Vyriad to develop oncolytic virus therapies
Regeneron Pharmaceuticals has formed a five-year alliance with Vyriad for the development of oncolytic virus-based...
Read More...
-
![Biogen signs commercialisation deal with Samsung Bioepis]()
Biogen signs commercialisation deal with Samsung Bioepis
Biogen has signed a commercialisation agreement with Samsung Bioepis for biosimilar candidates SB11 (ranibizumab) and...
Read More...
-
![non-hormonal menopause]()
Treating menopause: at last a non-hormonal alternative?
Despite the risk of breast cancer from long-term use of HRT to treat hot flushes,...
Read More...
-
![Artios ART inhibitor]()
Artios in-licenses MD Anderson-Shangpharma’s ART inhibitor programme
DNA damage response (DDR)-focused company Artios has in-licensed University of Texas MD Anderson and ShangPharma...
Read More...
-
![]()
Halozyme restructures following Phase III failure in pancreas cancer
San Diego-based biotech Halozyme has announced its metastatic pancreas cancer drug PEGPH20 failed to meet...
Read More...
Close
Close
Close
Go Top
